Thor: Erdafitinib In Metastatic Urothelial Cancer With Fgfr Alterations

THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations

THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations

ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations

European Society for Medical Oncology (ESMO)

An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma

Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC

THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

THOR-2 Cohort 3 interim analysis: erdafitinib in intermediate-risk NMIBC with FGFR3/2 alterations

Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations

BLC2001: erdafitinib for the treatment of metastatic urothelial carcinoma

Phase 3 THOR Study Results: Erdafitinib vs. Chemotherapy in Advanced Urothelial Cancer | CRSF 2024

CRSF - Cancer Research and Statistic Foundation

#ESMO21 Highlights on erdafitinib in adv. urothelial cancer with FGFRa alterations: The NORSE study

European Society for Medical Oncology (ESMO)

Targeted Therapy Option of Erdafitinib in Bladder Cancer #oncology #cancer #2023

OncBrothers: Practice-Changing Cancer Discussions

NORSE: erdafitinib and cetrelimab in metastatic urothelial cancer

NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations

The future role of erdafitinib in advanced urothelial carcinoma

TALAPRO-2 Study Design for 1L in mCRPC Patients - NOW FDA Approved | #oncology #cancer #2023

OncBrothers: Practice-Changing Cancer Discussions

Bladder Cancer Conference Highlights from ASCO 2023

Dana-Farber Cancer Institute

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malign...

Dr. Iyer on Erdafitinib-Related Hyperphosphatemia in Metastatic Urothelial Cancer